Recite me link

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Baricitinib [Olumiant]
f. Certolizumab [Cimzia]
g. Etanercept [Enbrel]
h. Etanercept Biosimilars
i. Filgotinib [Jyseleca]
j. Golimumab [Simponi]
k. Infliximab [Remicade]
l. Infliximab Biosimilars
m. Ixekizumab [Taltz]
n. Rituximab [MabThera]
o. Rituximab Biosimilars
p. Sarilumab [Kevzara]
q. Secukinumab [Cosentyx]
r. Tocilizumab [Ro Actemra]
s. Tofacitinib [Xeljanz]
t. Upadacitinib [Rinvoq]
u. Ustekinumab [Stelara]
Q2. Could you please provide the numbers of patients treated for Rheumatoid Arthritis ONLY in the last 3 months with the following drugs:
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Baricitinib [Olumiant]
e. Certolizumab [Cimzia]
f. Etanercept [Enbrel]
g. Etanercept Biosimilars
h. Filgotinib [Jyseleca]
i. Golimumab [Simponi]
j. Infliximab [Remicade]
k. Infliximab Biosimilars
l. Rituximab [MabThera]
m. Rituximab Biosimilars
n. Sarilumab [Kevzara]
o. Tocilizumab [Ro Actemra]
p. Tofacitinib [Xeljanz]
q. Upadacitinib [Rinvoq]

Download response Rheumatology. 240521